The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries

被引:16
作者
Fugger, Gernot [1 ,2 ]
Bartova, Lucie [1 ,2 ]
Fabbri, Chiara [2 ,3 ]
Fanelli, Giuseppe [2 ,4 ]
Dold, Markus [1 ]
Swoboda, Marleen Margret Mignon [1 ]
Kautzky, Alexander [1 ]
Zohar, Joseph [5 ]
Souery, Daniel [6 ,7 ]
Mendlewicz, Julien [6 ]
Montgomery, Stuart [8 ]
Rujescu, Dan [1 ]
Serretti, Alessandro [2 ]
Kasper, Siegfried [1 ,9 ]
机构
[1] Med Univ Vienna, Dept Psychiat & Psychotherapy, Vienna, Austria
[2] Univ Bologna, Dept Biomed & NeuroMotor Sci, Bologna, Italy
[3] Kings Coll London, Social Genet & Dev Psychiat Ctr, Inst Psychiat Psychol & Neurosci, London, England
[4] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Dept Human Genet, Med Ctr, Nijmegen, Netherlands
[5] Chaim Sheba Med Ctr, Psychiat Div, Ramat Gan, Israel
[6] Free Univ Brussels, Sch Med, Brussels, Belgium
[7] Psy Pluriel European Ctr Psychol Med, Brussels, Belgium
[8] Univ London, Imperial Coll Sch Med, London, England
[9] Med Univ Vienna, Ctr Brain Res, Spitalgasse 4, A-1090 Vienna, Austria
关键词
Major depressive disorder; Antidepressant treatment; Antidepressants; Selective-serotonin reuptake inhibitors; NEWER-GENERATION ANTIDEPRESSANTS; TREATMENT-RESISTANT DEPRESSION; SEROTONIN REUPTAKE INHIBITORS; PHARMACOLOGICAL-TREATMENT; INTRANASAL ESKETAMINE; UNIPOLAR DEPRESSION; SUICIDE RISK; EFFICACY; METAANALYSIS; MIRTAZAPINE;
D O I
10.1007/s00406-021-01368-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Due to favorable antidepressant (AD) efficacy and tolerability, selective-serotonin reuptake inhibitors (SSRIs) are consistently recommended as substances of first choice for the treatment of major depressive disorder (MDD) in international guidelines. However, little is known about the real-world clinical correlates of patients primarily prescribed SSRIs in contrast to those receiving alternative first-line ADs. Methods These secondary analyses are based on a naturalistic, multinational cross-sectional study conducted by the European Group for the Study of Resistant Depression at ten research sites. We compared the socio-demographic and clinical characteristics of 1410 patients with primary MDD, who were either prescribed SSRIs or alternative substances as first-line AD treatment, using chi-squared tests, analyses of covariance, and logistic regression analyses. Results SSRIs were prescribed in 52.1% of MDD patients who showed lower odds for unemployment, current severity of depressive symptoms, melancholic features, suicidality, as well as current inpatient treatment compared to patients receiving alternative first-line ADs. Furthermore, patients prescribed SSRIs less likely received add-on therapies including AD combination and augmentation with antipsychotics, and exhibited a trend towards higher response rates. Conclusion A more favorable socio-demographic and clinical profile associated with SSRIs in contrast to alternative first-line ADs may have guided European psychiatrists' treatment choice for SSRIs, rather than any relevant pharmacological differences in mechanisms of action of the investigated ADs. Our results must be cautiously interpreted in light of predictable biases resulting from the open treatment selection, the possible allocation of less severely ill patients to SSRIs as well as the cross-sectional study design that does not allow to ascertain any causal conclusions.
引用
收藏
页码:715 / 727
页数:13
相关论文
共 74 条
[1]   Agitated "unipolar" depression re-conceptualized as a depressive mixed state: Implications for the antidepressant-suicide controversy [J].
Akiskal, HS ;
Benazzi, F ;
Perugi, G ;
Rihmer, Z .
JOURNAL OF AFFECTIVE DISORDERS, 2005, 85 (03) :245-258
[2]   What happens next?: a claims database study of second-line pharmacotherapy in patients with major depressive disorder (MDD) who initiate selective serotonin reuptake inhibitor (SSRI) treatment [J].
Ball, Susan ;
Classi, Peter ;
Dennehy, Ellen B. .
ANNALS OF GENERAL PSYCHIATRY, 2014, 13
[3]   Combining psychopharmacotherapy and psychotherapy is not associated with better treatment outcome in major depressive disorder-evidence from the European Group for the Study of Resistant Depression [J].
Bartova, Lucie ;
Fugger, Gernot ;
Dold, Markus ;
Swoboda, Marleen Margret Mignon ;
Zohar, Joseph ;
Mendlewicz, Julien ;
Souery, Daniel ;
Montgomery, Stuart ;
Fabbri, Chiara ;
Serretti, Alessandro ;
Kasper, Siegfried .
JOURNAL OF PSYCHIATRIC RESEARCH, 2021, 141 :167-175
[4]   Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice [J].
Bartova, Lucie ;
Dold, Markus ;
Kautzky, Alexander ;
Fabbri, Chiara ;
Spies, Marie ;
Serretti, Alessandro ;
Souery, Daniel ;
Mendlewicz, Julien ;
Zohar, Joseph ;
Montgomery, Stuart ;
Schosser, Alexandra ;
Kasper, Siegfried .
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2019, 20 (06) :427-448
[5]   Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines [J].
Bauer, Michael ;
Severus, Emanuel ;
Moller, Hans-Jurgen ;
Young, Allan H. .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2017, 21 (03) :166-176
[6]   Mirtazapine orally disintegrating tablet versus sertraline:: A prospective onset of action study [J].
Behnke, K ;
Sogaard, J ;
Martin, S ;
Bäuml, J ;
Ravindran, AV ;
Ågren, H ;
Vester-Blokland, ED .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2003, 23 (04) :358-364
[7]   Mirtazapine compared with paroxetine in major depression [J].
Benkert, O ;
Szegedi, A ;
Kohnen, R .
JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (09) :656-663
[8]   Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity [J].
Bigos, Kristin L. ;
Pollock, Bruce G. ;
Aizenstein, Howard J. ;
Fisher, Patrick M. ;
Bies, Robert R. ;
Hariri, Ahmad R. .
NEUROPSYCHOPHARMACOLOGY, 2008, 33 (13) :3221-3225
[9]   Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials [J].
Bradley, Andrew J. ;
Lenox-Smith, Alan J. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2013, 27 (08) :740-758
[10]   The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature [J].
Carvalho, Andre F. ;
Sharma, Manu S. ;
Brunoni, Andre R. ;
Vieta, Eduard ;
Fava, Giovanni A. .
PSYCHOTHERAPY AND PSYCHOSOMATICS, 2016, 85 (05) :270-288